Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Biogen (NASDAQ:BIIB – Free Report) had its price target trimmed by HC Wainwright from $300.00 to $241.00 in a report issued ...

Biogen (NASDAQ:BIIB – Free Report) had its target price lowered by Truist Financial from $220.00 to $210.00 in a research ...

Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the ...

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $225 from $231 but keeps an Outperform rating on the shares after its Q4 ...

The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales ...

If an investor was to purchase shares of BIIB stock at the current price level of $134.51/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

Biogen's Q4 2024 EPS of $3.44 exceeded the forecast of $3.41. Revenue for the quarter reached $2.5 billion, marking a 3% growth from Q4 2023. Stock price declined by 5.98% in pre-market trading.